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ABSTRACT 
The most common inherited cardiac disorder, hypertrophic cardiomyopathy (HCM), is 
characterized by thickening of heart muscle, for which genetic mutations in cardiac myosin-
binding protein C3 (c-MYBPC3) gene, is the leading cause. Notably, patients with HCM display 
a heterogeneous clinical presentation, onset and prognosis. Thus, delineating the molecular 
mechanisms that explain how disparate c-MYBPC3 variants lead to HCM is essential for 
correlating the impact of specific genotypes on clinical severity. Herein, five c-MYBPC3 
missense variants clinically associated with HCM were investigated; namely V1 (R177H), V2 
(A216T), V3 (E258K), V4 (E441K) and double mutation V5 (V3+V4), all located within the C1 
& C2 domains of MyBP-C, a region known to interact with sarcomeric protein, actin. Injection 
of the variant complementary RNAs in zebrafish embryos were observed to recapitulate 
phenotypic aspects of HCM in patients. Interestingly, V3- and V5-cRNA injection produced the 
most severe zebrafish cardiac phenotype, exhibiting increased diastolic/systolic myocardial 
thickness and significantly reduced heart rate compared to control zebrafish. Molecular analysis 
of recombinant C0-C2 protein fragments revealed that c-MYBPC3 variants alter the C0-C2 
domain secondary structure, thermodynamic stability and importantly, result in a reduced 
binding affinity to cardiac actin. V5 (double mutant), displayed the greatest protein instability 
with concomitant loss of actin binding function. Our study provides specific mechanistic insight 
into how c-MYBPC3 pathogenic variants alter both functional and structural characteristics of 
C0-C2 domains leading to impaired actin interaction and reduced contractility, which may 
provide a basis for elucidating the disease mechanism in HCM patients with c-
MYBPC3 mutations.  
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Introduction 
 Hypertrophic cardiomyopathy (HCM) is a common inherited heart disease with an 
estimated prevalence of 2-5 per 1000 [1, 2] that is characterized by cardiac impairment linked to 
increased left ventricular wall thickness, diastolic dysfunction, interstitial fibrosis and myocyte 
disarray [3, 4]. Clinical presentation of HCM patients is heterogeneous, ranging from 
asymptomatic or mildly symptomatic, to distinct features such as dyspnea, angina, syncope, 
leading in some cases to progressive heart failure [1, 5, 6]. HCM is a genetic autosomal 
dominant disease characterized by extensive allelic heterogeneity affecting both sarcomeric and 
sarcomere-related proteins. Variants of the cardiac myosin binding protein C3 (c-MYBPC3) gene 
encoding the sarcomeric protein MyBP-C are the most common genetic cause of HCM, 
representing 40–50% of all HCM mutations [1, 7, 8]. Variants with different pathogenicity 
classification are associated with heterogeneous HCM clinical presentation, disease onset and 
prognosis [9-13]. Thus, analysis of structural-functional correlations is necessary to understand 
the molecular mechanisms by which these variants lead to HCM. It has been hypothesized that c-
MYBPC3 missense mutations directly disrupt the topology of MyBP-C by causing protein 
misfolding that impairs protein function [14]. The N-terminal domains of MyBP-C - C0, C1 
motif and C2 were previously found to play significant roles in regulating cardiac muscle 
contraction via their interaction with myosin [15] and actin [16], while its C-terminus was 
recently reported to directly interact with cardiac ryanodine receptor type 2 (RyR2) [17]. 
Considering the spectrum of HCM phenotypes described, we hypothesized that missense 
variation may disparately impact the structure of the protein and differentially affect its 
functional interactions [11, 18-20]; hence, in this study we selected five c-MYBPC3 variants 
linked with HCM for structural and functional characterization. Three variants (V1-3) (V1, 
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Arg177His; V2, Ala216Thr; V3, Glu258Lys) all located within the C1 domain, and V4 
(Glu441Lys) within C2 domain were identified in an Egyptian HCM study [21], while V5 is a 
double mutant (V3 & V4) that has been associated with a severe, early-onset HCM phenotype 
[11]. We hypothesized that these variants affect the biophysical and biochemical characteristics 
of MyBP-C, altering the functional properties of the C1 and C2 domains specifically leading to 
altered MyBP-C-actin association within the sarcomere. To characterize the in vivo effects of 
these variants, we employed a zebrafish model to elucidate morphometric consequences on 
cardiac function after synthetic mRNA injections. We also generated the mutant and wild-type 
N-terminal MyBP-C C0-C2 domains as recombinant proteins to examine their biophysical and 
biochemical properties, as well as their in vitro interaction with cardiac actin. Injection of 
zebrafish embryos with synthetic mRNA corresponding to the five MyBP-C variants produced 
atypical cardiac morphology and impaired cardiac function recapitulating the human HCM 
phenotype. Collectively, our results provide insight into the molecular impact of variant-specific 
c-MYBPC3 genotype on MyBP-C biophysical characteristics, protein stability and functional 
interaction with cardiac actin, contributing to a better understanding of HCM genotype-clinical 
severity correlation.  
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Experimental 
Materials and methods 
Classification of identified variants 
 We used the ClinVar database (https://www.ncbi.nlm.nih.gov/clinvar/) for c-MYBPC3 
variant selection with variable pathogenicity classification as: pathogenic, nonpathogenic, or as a 
variant of unknown clinical significance (unlikely to be pathogenic, uncertain, likely to be 
pathogenic).  
 
Zebrafish model  
 All procedures were performed in conformity with the AAALAC International, Guidance 
on the housing and care of Zebrafish (Danio rerio) [22]. The study protocol was approved by 
Qatar University IACUC Office under project approval number QU-IACUC 015/2014. Zebrafish 
were raised and maintained at 28°C on a 14:10-h light-dark cycle and fed Artemia nauplii. Wild-
type (AB) strain of zebrafish was used for our experiments. 
  
Human c-MYBPC3 missense mutation in vitro transcription of mRNA  
Wild-type (WT) c-MYBPC3 cDNA (NM_001044349) and the five mutant constructs 
were cloned into pcDNA-DEST47 vector (Life Technologies) to generate  human WT c-
MYBPC3 mRNA and mRNA encoding the four single missense variants : V1 (c.530G>A), V2 
(c.646G>A), V3 (c.772G>A), V4 (c.1321G>A) as well as the double variant V5 (c.772G>A + 
c.1321G>A) (Figure 1). RNA transcription was performed using the mMESSAGE 
mMACHINE T7 Transcription Kit, Cat # AM1344 and Poly(A) Tailing Kit, Cat 
# AM1350 (ThermoFisher Scientific). 
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Morpholino design and synthetic mRNA injection 
 The c-mybpc3 morpholino (MO:5’-CTCTGGCATCCTGGTTGAGTGTCCC-3’, Gene 
Tools, USA) targeted against the translational start site was injected into WT strain zebrafish 
embryos at one cell stage to knock down zebrafish endogenous c-mybpc3 [23]. In the mRNA 
experiments, c-mybpc3 MO (2.5 ng) was co-injected with human c-MYBPC3 mRNA (100 pg) 
for the corresponding missense c-MYBPC3 variants. At least 50 embryos were injected in each 
group.  
 
Quantitative measurements of zebrafish cardiac size and function 
 Injected zebrafish embryos were raised at 28°C for 3 days and individually removed from 
the 28°C incubator immediately prior to measurement to minimize the effect of environmental 
temperature on cardiac function. Zebrafish embryos were mounted in 3% methylcellulose prior 
to imaging. The cardiac phenotypes were recorded at 60 frames/second for 3 seconds at 150 X 
using a stereomicroscope (SteREO Zeiss LUMAR.V12) equipped with USB 2.0 monochrome 
camera (The Imaging Source). 
 
Measurement of zebrafish ventricular myocardial thickness 
 Structural analysis of the zebrafish ventricle was performed by analysis of 2D images at 
specific time points. Recorded videos were imported into Image J software (version 1.45s public 
domain software, http://imagej.nih.gov/ij) and ventricular end-diastole and ventricular end-
systole images were extracted. The endocardial and myocardial boundaries were traced to 
calculate the ventricular wall thickness as the average thickness between these two regions.  
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Heart Rate Measurements 
 Recorded videos were imported into DanioScope software (Noldus, version 1.0.109) as a 
compressed AVI file, where a subset of the beating heart was outlined and heart rate was 
calculated. 
 
Statistical analysis 
 Statistical analysis was performed using GraphPad Prism 7. Multiple group comparisons 
were analyzed by one-way ANOVA. Significant difference between groups was expressed using 
p values: *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
 
Molecular Modeling 
 The complex MyBP-C structure of C1-C2 domains was obtained from our previous 
molecular dynamics study of 10ns simulations at physiological conditions, with all the 
parameters as described earlier [11]. The representative structures of WT MyBP-C and its 
variants from the molecular dynamics simulations were selected using cluster analysis. In this, 
1000 structures of each variant trajectory were classified into clusters based on their structural 
deviations. A structure from the top ranked cluster was chosen for representation, as it was a 
frequently occurring conformation. These simulated structures utilized PyMol (www.pymol.org) 
for analysis of the secondary structural elements. To quantify the structural components, we used 
a secondary structure assignment program in PyMOL (“STRIDE”) to calculate all the elements. 
In addition, to map the structural deviations of variants from the WT, we used molecular 
superposition of the representative structures by aligning using the graphical interface in 
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PyMOL. All protein cartoons were generated with high ray trace mode with depth cue to give 3D 
representation of the molecular models.     
 
Plasmid construction 
 Human c-MYBPC3 cDNA (NM_001044349) was amplified by PCR from pcDNA-
DEST47, using Phusion polymerase (Finnzymes) and the appropriate primers to incorporate 5’-
EcoRI and 3’-NotI sites. c-MYBPC3 was then cloned into pHSIE vector. The primers used for 
the amplification of c-MYBPC3 were: 5’-
GGAAGGTACCATGGCTGATCAGCTGACCGAAG-3’ (forward) and 5’-
GCAAGCGGCCGCTCATTTTGCAGTCATCATCTGTAC-3’ (reverse). 
 
Prokaryotic expression, purification and intein cleavage of MyBP-C C0-C2 domain 
recombinant proteins 
 For MyBP-C-fusion protein expression (6xHis-SUMO2-intein-C0-C2), Escherichia coli 
[BL21-CodonPlus(DE3)-RILP; Stratagene] were transformed with the appropriate plasmid. The 
presence of the SUMO fusion-tag facilitated enhanced solubility of the recombinant protein in 
bacterial cells [24, 25]. Cells were cultured at 37 °C until the optical density at 600 nm reached 
0.6. Fusion protein expression was then induced for 18 h at 16°C with 0.1 mM IPTG (isopropyl 
β-D-thiogalactopyranoside). Bacterial cell pellets were harvested by centrifugation at 6,000 g for 
15 minutes, 4°C and then resuspended in 20 ml of buffer A (50 mM Tris, pH 8.5, 300 mM NaCl, 
25 mM imidazole). Cells were lysed by mild sonication then partitioned into soluble and 
insoluble fractions by centrifugation at 20,000 g for 20 minutes at 4°C and the supernatant 
containing the soluble protein fraction was transferred into a fresh tube. Supernatant was then 
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applied to a 1ml Ni–NTA column pre-equilibrated in buffer A. To avoid auto-cleavage by intein 
protease, all the following purification steps were performed at 4°C using ice-cold buffers. After 
binding, the column was washed with 10 x column volumes of buffer A followed by an 
additional wash (10 x column volumes) of cleaving buffer (PBS buffer supplemented with 40 
mM Bis-Tris and 25 mM imidazole, pH 6.0). After the second wash, the column was sealed and 
incubated at room temperature for 3 h to allow intein cleavage. After intein cleavage, 5 ml of 
cleaving buffer was used to elute the cleaved C0-C2 (MyBP-C) proteins from the resin. The 
remaining proteins bound to the column were eluted with 10 ml of cleaving buffer supplemented 
with 500 mM imidazole, and the eluted fractions were collected and analysed by 12% SDS–
PAGE electrophoresis. 
 
Western Blotting  
 Purified recombinant MyBP-C C0-C2  proteins were analyzed by SDS-PAGE 
electrophoresis with Coomassie Brilliant Blue staining and immunoblot analysis performed as 
described previously [26]. Proteins were probed with a polyclonal anti-MyBP-C antibody 
(1:1,000 dilution) (Abgent, Cat # AP12436a) and immunoreactive proteins were detected by 
ECL Chemiluminescence Detection Kit (Thermofisher Scientific, Cat #32106). 
 
Circular Dichroism (CD) Analysis 
 CD measurements were conducted using a JASCO-715 spectropolarimeter with a Peltier 
type cell holder. Wavelength scans in the 190 nm to 260 nm range (far-UV region) were 
performed in Quartz SUPRASIL (HELLMA) precision cells of 0.1 cm path length, using a 
wavelength step of 0.2 nm, a scan rate of 20 nm min−1, response time 1 s and 1 nm bandwidth. 
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Buffer spectra were collected and subtracted from all scans. The concentration of all protein 
samples was 0.2 mg/ml. 
 Thermal denaturation data were collected by heating the protein sample from 20° to 90°C 
using a scan rate of 1.5 K/min and monitoring signal changes at 208 nm. Spectral parameters for 
these measurements were: 1 s step resolution, 0.5 s response time, sensitivity 25 mdeg and 
bandwidth 1 nm. Data analysis software (CDNN version 2.1) was used to deconvolute the 
collected far-UV CD spectra in order to determine the protein’s α-helix, anti and parallel β-sheet, 
β-turn and random coil content.  
  
Chemical Denaturation 
 Fluorescence spectra were collected on a PTI QuantaMaster 400 steady-state 
fluorescence system. Tryptophan was selectively excited at 295 nm and emission spectra were 
collected between 310 to 450 nm using a 4 ml quartz cuvette (Hellma) with a path length of 10 
mm. Scan rate was set to 100 nm min−1 with a response time of 1 sec. Slit width for both 
emission and excitation were 2 nm. The protein species concentration used for all fluorescence 
experiments was 0.2 mg/ml. All fluorescence spectra were corrected for background intensity as 
measured with pure buffer. In a typical experiment, small amounts of an 8 M guanidine 
hydrochloride solution were gradually added in the cuvette along with the appropriate amount of 
concentrated protein solution in order to keep the MyBP-C concentration in the cell constant. 
The mixture was stirred using a small magnetic stir bar for 1 min and incubated in the dark for 
15 min, at which point the fluorescence emission spectrum of the sample was collected. The 
titration was carried on until a 5 M final concentration of guanidine hydrochloride was reached 
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inside the cuvette. Mock titrations with the addition of buffer instead of guanidine hydrochloride 
were collected and the corresponding spectra were subtracted from the original data.  
The final data were fitted using the following equation [27]: 
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where: ΔG = m([D50%] – [D]), [D] is the concentration of the denaturant in the cuvette, [D50%] is 
the concentration of denaturant at the midpoint of the transition, m is the slope of the 
denaturation transition, R is the universal gas constant, T is the experimental temperature, aN and 
bN the intercept and slope of the native state baseline, while aD and bD are the corresponding 
values of the denatured state baseline. 
 
Co-sedimentation Cardiac Actin Binding Assays 
 Co-sedimentation assays were performed as previously described [28]. Actin Binding 
Protein Biochem Kit (Cytoskeleton, Cat # BK001) and bovine cardiac actin (Cytoskeleton, Cat # 
AD99-B) were used. Bovine cardiac actin was prepared in General Actin Buffer (5 mM Tris-HCl 
pH 8.0, 0.2 mM CaCl2) (Cytoskeleton, Cat # BSA01) and supplemented with 0.2 mM ATP and 
0.5 mM DTT prior to use. Purified N-terminal C0-C2 MyBP-C protein fragments were dialyzed 
using Vivaspin tubes (Sartorius, Vivaspin 20). Initially, optimization experiments were 
performed using 2 μM of wild type MyBP-C C0-C2 and 1, 10, 20 or 30 μM c-actin, in order to 
identify the optimal concentration in which saturated binding between MyBP-C and c-actin is 
achieved. After the optimal concentrations were determined, 30 μM of c-actin was incubated 
with 2 μM of each MyBP-C C0-C2 recombinant protein (wild-type and mutants) for 30 min at 
room temperature. For our co-sedimentation experiments, incubation of c-actin with α-actinin 
12 
 
protein served as our positive control, while incubation of c-actin with BSA served as our 
negative control. After incubation, samples were centrifuged at 14,000 g for 1 hour at 24 °C. 
Supernatants were carefully removed, mixed with 10 μl of 5 x Laemmli reducing-sample buffer 
and analyzed by SDS-PAGE electrophoresis and Coomassie brilliant blue staining. Finally, to 
estimate the relative binding of c-actin to the various recombinant proteins, band intensities 
appearing in the stained gels were measured by densitometric analysis and the data analyzed 
using GraphPad Prism 7. 
 
Results 
c-MYBPC3 variants are associated with distinct HCM phenotype  
 The elucidation of genotype-phenotype associations provides a crucial parameter to help 
predict the impact of a specific variant on HCM clinical severity. To investigate the mechanism 
by which different c-MYBPC3 variants lead to cardiac impairment, we studied four single 
missense mutations: V1 (c.530G>A, p.R177H), V2 (c.646G>A, p.A216T ), V3 (c.772G>A, 
p.E258K), V4 (c.1321G>A, p.E441K) in addition to a double mutation V5 (V3+V4), (Figure 1). 
HCM patients expressing these variants exhibited a range of clinical symptoms and variable 
degrees of ventricular hypertrophy as determined by septum and wall thickness (Table 1). 
Multiple in silico algorithms, and/or population frequency databases defined the five variants’ 
pathogenicity classification that varied from uncertain significance to certainly pathogenic. 
Furthermore, the patient carrying the double mutation (V5) had an early-onset disease at age 21 
and died at the age of 42. Conversely, patients carrying single mutations (V1, V2, V3, and V4) 
had lower severity symptoms leading to heart failure later on in life (Table 1) suggesting that 
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patients expressing different c-MYBPC3 variants can present with typical HCM clinical 
heterogeneity in regard to disease severity, onset and prognosis.  
 
 
 
Modeling HCM patients’ c-MYBPC3 variants using zebrafish  
 Zebrafish (Danio rerio) is a powerful vertebrate animal model to study cardiac function 
due to its embryonic transparency [29]. To assess variants’ genotype-phenotype associations, we 
injected synthetic mRNA encoding c-MYBPC3 variants at the zebrafish one-cell stage and 
examined their cardiac morphology and function. The injection of synthetic mRNA resulted in 
aberrant cardiac morphology with altered ventricular sizes and function when examined at 3 days 
post-fertilization (dpf) (Figure 2, supplemental video 1). V1, V2 and V4 displayed notably 
different ventricular morphology to the control group. However, V5 and V3 exhibited a greater 
disparity in ventricular phenotype compared to other variants (Figure 2B, supplemental video 1). 
These results demonstrate that c-MYBPC3 V5 and V3 zebrafish cardiac phenotypes correlate 
with their pathogenicity classification in HCM patients, as both are predicted to be pathogenic 
class 5 (Table 1). Thus, expression of these variants in the zebrafish model essentially 
recapitulated the HCM pathological cardiac phenotype in comparison to controls (Figure 2A-B). 
 
Zebrafish c-MYBPC3 models develop increased ventricular myocardial thickness  
 Cardiac morphometric measurement of the ventricular myocardial wall thickness of c-
MYBPC3 variant-injected embryos was determined at both diastole and systole (Figure 2C-D). 
All c-MYBPC3 variants resulted in a significantly increased ventricular myocardial thicknesses 
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in comparison to control group. The V5 (V3 & V4) double mutation, and V3 (E258K) exhibited 
the most severe myocardial hypertrophic phenotype with increased diastolic / systolic 
myocardial thickness at 15.6 / 14.6 μm (p<0.0001) and 14.2 / 12.9 μm (p<0.0001), respectively. 
While thickness for V1 (R177H) was 12.7 / 12.5 μm (p<0.0001), V2 (A216T) yielded 11.5 / 11.7 
μm (p<0.001) and V4 (E441K) displayed 12.1 / 12.3 μm (p<0.0001) in contrast to control 
zebrafish at 10.1 / 9.5 μm (Figure 2C-D). Zebrafish cardiac phenotype resembled the human 
ventricular hypertrophic phenotype as HCM patients exhibit increased myocardial wall thickness 
with a heterogeneous clinical presentation among patients [30]. 
 
Zebrafish c-MYBPC3 models develop impaired cardiac contractility  
 To examine whether the c-MYBPC3 variants elicit different effects on cardiac function, 
we assessed the heart rate of injected zebrafish as an indicator of cardiac contractile impairment. 
Introduction of both V3 and V5 synthetic mRNA significantly affected the average heart rate 
resulting in a 23% reduction for both groups; 113 beats per minute (bpm) compared to the level 
observed in zebrafish controls at 146 bpm. In contrast, there was a moderate decrease (<10%) for 
V1, V2, and V4, at 138, 143 and 133 bpm, respectively; however, these still represent cardiac 
contractile impairment (Figure 2E). These findings suggest that genotype specificity contributes 
to HCM phenotypic severity as the V5 double mutation produces early-onset and progression to 
end-stage HCM (Table 1). Indeed, mRNA injection corresponding to V5 variant in zebrafish 
resulted in the most severe heart rhythm impairment (Figure 2B-E). 
 
Bioinformatics analysis of c-MYBPC3 variant effect on functional domains 
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 The severe phenotypes of V3 and V5 led us to study structure-function relationships at 
protein level, which may reveal molecular determinants that underlie genotype to phenotypic 
expressions. Several studies have reported that the region C1-C2 of MyBP-C plays a central role 
in the interactions with actin and myosin proteins within the sarcomere [31, 32]. Our molecular 
model of the C1-C2 region of the WT protein suggests this linker segment (MyBP-C motif) may 
hold the key sites for protein phosphorylation (Figure 3A). The secondary structural elements of 
the domains C1 and C2 in the WT comprises β-sheets, however, the linker/motif is highly D-
helical in nature. Both the V3 and V5 molecular models deviated structurally and were arranged 
differently from WT, with the majority of these rearrangements observed in the motif region 
(Figure 3B-C). The variants induced changes in the secondary structural elements of the C1 and 
C2 domains and in the intervening motif region, where the impact was in particular, higher in V5 
(Figure 3C) in comparison to V3. Interestingly, V3 appeared to be flexible, while V5 appeared to 
be rigid compared to WT in the RMSD (root mean square deviation) calculation of the 
representative structures from molecular dynamics simulations (Figure 3D). The secondary 
structural changes shown in the graph (Figure 3E) provides an overview of the intra-molecular 
consequences that induce structural rearrangements in both V5 and V3. Here, the V3 model 
presents reduced β-sheets and increased coils compared to WT, whereas V5 showed inverse 
behavior. This correlates with our deviation analysis and reflects V3 flexibility with increase of 
coils, and the rigid V5 upon reduction of coils with increased E-sheets. Overall, this protein 
modeling helps to provide a molecular insight into the structural consequences of MyBP-C 
variants.   
 
Circular dichroism (CD) spectroscopy and thermal stability analysis of MyBP-C variants 
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 To investigate the impact of these c-MYBPC3 variants on the biophysical and 
biochemical properties of WT MyBP-C protein, we generated prokaryotic expression plasmid 
constructs encoding the C0-C2 N-terminal domains of WT and the five variants (Figure 4A). The 
purified recombinant C0-C2 fragment proteins were highly soluble and migrated on SDS-PAGE 
according to their predicted molecular weight of ׽50 kDa, as shown in both Coomassie stained 
gel and western blot analysis using MyBP-C N-terminal antibody (Figure 4B). To better 
understand the structural effects of these c-MYBPC3 variants, we measured far-UV CD spectra 
(Figure 4C) and we determined the secondary structure elements (Table 2) of all protein samples 
at 25°C. It was evident that all variants disrupted the native structure of the C0-C2 proteins, 
leading to conformations with significantly different secondary structure characteristics when 
compared to WT (Table 2). At elevated temperatures (~90°C), all protein species retain most of 
their secondary structure characteristics (Supplemental material, Tables 1-6). However, for WT, 
V1 and V2, we observed an increase in random coil content with a concurrent loss of helicity, 
reflecting partial unfolding of the structure. At the same time, the β-sheet content of the protein 
fragments remained relatively intact, revealing a central core of β-sheets with high thermal 
stability. For V3, V4 and V5 only small changes in the secondary structure content were 
observed. This was also evident from the relatively small molar ellipticity change recorded in the 
far-UV spectra throughout the 20°C - 90°C temperature range. Most likely, the observed changes 
involved spatial rearrangement of the secondary structure elements without significant unfolding. 
CD melting curves were collected to analyze the thermal denaturation profiles at 208 nm over 
the temperature range 20°C - 90°C (Figure 5). The relative signal change for V3, V4 and V5 was 
small, resulting in curves with lower signal to noise ratio than the corresponding profiles of WT, 
V1, and V2. The thermal denaturation curve of WT, V1, V2, V3 and V4 revealed the presence of 
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two consecutive unfolding transitions; the first thermal transition occurs in the temperature range 
50°C - 65°C with the second at 65°C - 90°C. Interestingly, in contrast to other variants, the 
melting profile of V5 exhibits only the unfolding transition at 50°C - 65°C, suggesting that no 
further protein aggregation occurred after ~60°C for this fragment. A possible mechanism for 
this complex thermal behavior involves the formation of oligomers from monomer protein 
fragments (first transition). As the temperature of the sample increases, partial unfolding and 
structural rearrangements of the proteins, dictated by further changes in their aggregation state, 
result in a second thermal transition. A similar thermal behavior has been previously reported for 
other MyBP-C motifs [33, 34] with dynamic light scattering studies confirming the formation of 
aggregates upon heating [34].  
 
Chemical denaturation profiles for the WT and mutant MyBP-C proteins 
 To determine the thermodynamic stability of mutant MyBP-C protein fragments, we 
tested the reversibility of chemically-induced transitions to calculate the Gibbs free energy 
change (ΔG) of the unfolding process (Table 3). Chemical denaturation profiles of WT and 
MyBP-C recombinant fragment proteins exhibited transitions that were completely reversible 
and under thermodynamic control, with all samples recovering their initial spectra after dialysis 
into their original buffer (Figure 6). Interestingly, except for V5, chemical denaturation of all 
variants lead to conformations with increased stability compared to the WT MyBP-C fragment. 
Notably, V3 and V4 showed a significant increase in ΔG (~1.5 kcal/mol), while for V1 and V2 
this change was less than 0.6 kcal/mol, slightly above the statistical error for these 
measurements. The recorded V5 destabilizing effect is small and lower than the corresponding 
statistical error, indicating that V5 has practically no impact on the thermodynamic stability of 
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MyBP-C. Thermodynamic analysis for the chemical-induced denaturation of all fragments 
(Table 3) showed ΔG values lower than the typical 5-15 kcal/mol found for most proteins [27]. 
 
MyBP-C variants affect cardiac function through impaired actin binding  
 MyBP-C is a multi-domain protein with vital structural and regulatory roles. The selected 
variants are located within the N-terminal region, which encompasses the C1-C2 domains of 
MyBP-C that is involved in regulating cardiac muscle contraction through interaction with actin 
within the sarcomere (Figure 4A). The recombinant C0-C2 domains have been previously shown 
to interact with actin [16]. Thus, we hypothesized that impaired cardiac function phenotypes may 
be correlated with a reduced ability of MyBP-C to interact with actin. To investigate the specific 
effects of the variant’s structural alterations on actin binding properties, we employed a co-
sedimentation assay. In this assay, c-actin can be co-sedimented due to its filamentous nature, 
whereas non-filamentous or non-interacting proteins remain in the supernatant. In the absence of 
c-actin, WT MyBP-C C0-C2 recombinant protein remained in the supernatant fraction. However, 
when cardiac actin was added to the assay, WT MyBP-C C0-C2 recombinant protein specifically 
bound and co-sedimented with c-actin as the recombinant protein was detected in the pellet. 
After a series of optimization experiments, we found that 2 PM of MyBP-C recombinant C0-C2 
domains can specifically bind to 30 PM actin in a fully saturated manner (Figure 7A). 2 μM of 
each MyBP-C C0-C2 recombinant protein (WT and mutants) was incubated with c-actin at RT 
for 30 min and centrifuged for 1 hour at 14,000 g. The experiment was repeated with a different 
batch of recombinant proteins. The amounts of MyBP-C C0-C2 fragments in the supernatant 
fractions (unbound fractions) were analyzed by SDS-PAGE and quantified by Coomassie 
brilliant blue (Figure 7B) and densitometric analysis (Figure 7C). Following densitometric 
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analysis and % normalization of the binding of MyBP-C C0-C2 recombinant proteins to c-actin 
(Figure 7C), we found that except for V1, all the other variants (V2, V3, V4 and V5) displayed 
significantly reduced c-actin binding, with V4 and especially V5 showing the most dramatic 
reductions (~38 and 52% reduction of their c-actin relative binding affinities, respectively). 
 
 
 
Discussion 
 HCM is a genetically heterogeneous autosomal dominant cardiac disease [4, 35], with 
many c-MYBPC3 variants previously reported in HCM patients [1, 8]. Since HCM clinical 
presentation in patients is also heterogeneous, it is hypothesized that severity is correlated to 
underlying genetic mutations. Previous studies demonstrated that patients carrying specific 
mutations have been associated with earlier disease presentation, poorer prognosis, severe 
disease phenotype, higher prevalence of a family history and sudden cardiac death [32, 36, 37]. 
Furthermore, most of the childhood-onset disease mutations are missense (~76%), while ~60% 
of previously reported mutations in adults encode for MyBP-C truncations. This observation 
suggests that c-MYBPC3 missense mutations causing HCM may be more severe than truncating 
mutations, explaining the earlier age of onset [38]. Some studies have established potential 
correlations in interpreting the phenotypic effect of these variants. However, the exact 
mechanism by which these variants affect MyBP-C physiological functions within the sarcomere 
leading to the different clinical phenotypes still remains unclear.  
 Our current study presents a new model of an in vitro functional genomics approach to 
investigate the effects of specific genotypes on MyBP-C biophysical and biochemical 
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characteristics that may explain HCM clinical severity. We selected five c-MYBPC3 variants 
(Figure 1) that represented HCM heterogeneity with different pathogenicity classifications, as V3 
and V5 (double mutant) were classified as the most pathogenic variants [11, 18-20]. Importantly, 
the double mutant V5 and the single mutant V3 exhibited the most severe myocardial 
hypertrophic phenotype (Table 1). Molecular modeling suggested critical structural 
consequences for these two variants (Figure 3). Furthermore, our biophysical analysis revealed 
that all variants lead to distinct protein conformations affecting the secondary structure content 
(Figure 4) and the thermodynamic stability (Figure 5) of the MyBP-C C0-C2 recombinant 
proteins. Consequently, distinct alterations of the MyBP-C C0-C2 fragments binding affinity to 
cardiac actin were observed when we investigated the protein interaction of these variants to 
cardiac actin (Figure 7).  
 Using different techniques of the zebrafish ‘toolbox’, we were able to recapitulate the 
different HCM phenotypes in the zebrafish model. All c-MYBPC3 variants resulted in aberrant 
zebrafish cardiac morphology with altered ventricular size and function (Figure 2, supplemental 
material, 1). Our zebrafish experiments explored allele pathogenicity and captured specific 
cardiac phenotypes as effects that are variant-specific. The resultant zebrafish cardiac phenotype 
accurately resembled the human ventricular hypertrophic phenotype given that HCM patients 
exhibit increased myocardial wall thickness. Notably, V5 (E441K & E258K) and V3 (E258K) 
resulted in the most dramatic zebrafish cardiac impairment presenting with increased ventricular 
dimension in comparison to other variants. The V5 and V3 diastolic/systolic myocardial 
thickness was significantly increased and both variants exhibited significant contractile 
dysfunction with decreased heart rate in contrast to the other variants and wild-type MyBP-C. 
These results support the established class 5 pathogenicity of these two variants (Table 1). 
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Collectively, our zebrafish functional validation suggests an association of genotype to a disease 
phenotype; and confirmed the in-silico tools of pathogenicity classification of a specific genetic 
variant. Our findings support previous studies of other MyBP-C variants associated with a severe 
clinical phenotype [39]. Previous studies have demonstrated that each individual c-MYBPC3 
patient’s phenotype varies with the position of the mutation and its cognate functional domain. It 
has been suggested that possessing multiple disease-causing sarcomere mutations may be 
associated with a greater risk for severe disease progression, including sudden cardiac death. 
This can be interpreted as double (or compound) variants exerting a gene dosage effect in HCM 
patients [9, 37, 40]. Recent reports using molecular modeling together with clinical and 
expression data revealed that the missense mutations in the C1-C2 of MyBP-C could be 
responsible for the severe symptoms studied in selected HCM patients [11, 13, 32]. Accordingly, 
our study particularly highlights the variants-induced secondary structural modifications in detail 
and reveal conformational rearrangements of the variants V3 and V5 (enhanced impact), which 
lead to severe effects on the motif region. As reported previously by many studies [31, 41], this 
motif is a key location for protein phosphorylation and for interaction with actin and/or myosin 
which serve to regulate the mechanism of muscular contractions. Therefore, the observed data 
from our modeling and CD-spectroscopy collectively suggest variation-induced secondary 
structural changes could be detrimental to function, explaining the abnormal phenotypes that we 
observed in our diseased models of zebrafish. Earlier molecular modeling suggested that V1 and 
V2 might increase the intra-molecular rigidity due to induced structural changes, resulting in 
minimal effect on the surface electrostatic properties that are key for binding with actin [13]. 
Contrastingly, V3 was predicted to significantly alter the structural properties leading to major 
change in C1 surface and malfunction of the protein [42]. Significantly, modeling of V5 
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conformational changes of C1-C2 domains predicted alterations of the binding of these domains 
to other MyBP-C domains and other sarcomeric proteins (actin and myosin), in particular by 
affecting the nearby motif region. These effects possibly explain the early onset and the severity 
of the observed HCM phenotype [11].  
By using the zebrafish model to study the effects of these MyBP-C variants, our data indicate 
correlation of phenotypic variations to specific molecular mechanisms of altered protein 
characteristics and binding interactions with c-actin. The recombinant N-terminal, C0-C2 
fragment, of V5 and V3 confirmed the model of altered secondary structural elements of the 
protein. As a result, V5 had only one unfolding transition step in the thermal denaturation curve 
compared to the other variants, which demonstrated two consecutive unfolding transitions. These 
observations highlight the fact that these missense variants result in altered protein 
conformations, which could potentially affect MyBP-C physiological functions within the 
sarcomere. MyBP-C is a multi-modular structural protein of 11 domains regulating sarcomere 
organization and contractility [1, 15, 43, 44]. It was previously shown that the N-terminal 
complex, C1-C2 of MyBP-C, regulates cardiac muscle contraction through actin interaction 
within the sarcomere [15, 28, 45, 46].  Our in vitro MyBP-C/cardiac actin co-sedimentation 
assays confirmed the negative effect of V2, V3, V4 and V5 mutations on the intermolecular 
interactions of MyBP-C with c-actin and more importantly highlighted the severe effect of the 
double mutation, V5. Accordingly, V5 relative binding affinity to c- actin was reduced almost 
52% when compared to that of WT. In contrast, V1 variant did not exhibit any significant 
reduction on its relative binding affinity to c-actin suggesting alternative disease mechanisms 
rather than altered c-actin binding affinity. As recent studies have shown a significant overlap 
between the N-terminal of MyBP-C and actin as well as myosin S2 binding sites [47], further 
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analysis should be considered to study the impact of these variants on their interaction with 
myosin. Interestingly, despite the fact that we detected a significant reduction of V3 relative 
binding affinity to c-actin  (~27%), earlier studies using the yeast two-hybrid system indicated 
that MyBP-C N-terminal E258K variant (V3) had reduced affinity to myosin heavy chain sub-
fragment 2, providing a potential alternative mechanism underlying the HCM disease phenotype 
[48]. Our findings might begin to explain the contractile dysfunction resulting from the different 
c-MYBPC3 variants as a result of their divergent biochemical and biophysical characteristics. 
Interestingly, the effect of the five mutations on cardiac phenotype in our experimental zebrafish 
model is consistent with previously reports on the patients’ clinical severity. 
Conclusion 
Although MyBP-C protein has been extensively studied, the exact molecular 
mechanism(s) by which MyBP-C missense variants lead to severe cardiac disease remain 
elusive. This is largely due to the lack of a comprehensive understanding of the impact of these 
mutations on the protein molecular characteristics, as well as on its interactions with other 
sarcomeric components. 
Our current study has clearly demonstrated that the zebrafish model is a very useful in 
vivo ‘tool’ to prognose and characterize the pathogenicity of MyBP-C missense mutations 
identified in patients with cardiac disease. It also provides further evidence for the important role 
of MyBP-C N-terminal C0-C2 domain on the vital interaction of this protein with actin within 
the sarcomere. However, taking into consideration that our observations are based on the in vitro 
biochemical and biophysical characterization of the isolated C0-C2 domains of MyBP-C protein 
and not of the full-length molecule, further in vivo studies are required to confirm and expand on 
our findings. We cannot exclude the possibility that the behavior of the full-length wild type 
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MyBP-C protein and its corresponding variants might be very different in vivo, necessitating 
further in vivo functional analysis, which will shed more light into the molecular mechanism(s) 
that mutations in c-MYBPC3 gene lead to severe cardiac disease. 
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Table Legends 
Table 1. Hypertrophic cardiomyopathy associated c-MYBPC3 missense mutations location, 
classification and clinical characteristics. a: variant (V) reported at ClinVar database 
(https://www.ncbi.nlm.nih.gov/clinvar/), b: V5, patient carrying double mutation of V3 and V4, 
c: reference sequence NM_000256.3, d: protein sequence NP_000247.2, e: frequency allele 
reported at ExAC = Exome Aggregation Consortium (http://exac.broadinstitute.org), N/R (not 
reported), f: age of disease onset, g: cardiac septum thickness, h: interpretation of sequence 
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variants pathogenicity based on American College of Medical Genetics and Genomics (ACMG) 
guidance. 
 
Table 2. Secondary structure elements for all recombinant proteins at 25°C. 
 
Table 3. Thermodynamic parameters calculated from chemical denaturation experiments 
for WT and MyBP-C variants. 
 
 
Figure Legends 
Figure 1. Location of hypertrophic cardiomyopathy associated mutations. Schematic 
illustration  showing A. Cardiac myosin binding protein C3 (c-MYBPC3), showing the location 
of hypertrophic cardiomyopathy variants in Human Genetics Variants Society (HGVS) format, 
The c-MYBPC3 is composed of 35 exons, where these variants are located within exon 5, 6 and 
13. B. MyBP-C protein consists of 11 domains (C0-C10); 8 immunoglobulin-like domains 
(IgC2-like) and 3 fibronectin type III-like (FN3) domains with N-terminal Proline-Alanine rich 
linker sequence and the regulatory Motif that includes the phosphorylation sites indicated by 
asterisks. All variants in this study are within the C1-C2 domains. 
 
Figure 2. Expression of c-MYBPC3 variants in the zebrafish model recapitulated the 
human HCM phenotype. A. Zebrafish injected with human c-MYBPC3 synthetic RNA of wild 
type and the five variants at one cell stage. At 72 hours post fertilization, larvae were mounted 
posteriorly to image ventricle chamber of the heart (black box). B. Representative images of 
aberrant heart morphology of the five expressed variants in comparison to control group. C. 
Cardiac functional analysis of  variants expressed in zebrafish, the measurement of  ventricular 
diastolic myocardial thickness for  V5 (double mutation E441K & E258K) and V3 (E258K) were 
the most significantly increased mean followed by V1 (R177H), V4 (E441K) and V2 (A216T) in 
comparison to WT. D. Ventricular systolic myocardial thickness measurement for V5 were the 
most significantly increased mean at 14.6 μm followed by V3, V1, V4 and V2 in comparison to 
WT. E. Heart contractile measurement showed that both V5 and V3 significantly impacted the 
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average heart rate in injected zebrafish demonstrated by the significant reduced heart rate mean 
measured by beats per minute (bpm) compared to WT. While, V1, V2 and V4 heart rates were 
still less than the control zebrafish. Cardiac function analyses were represented in Box – Whisker 
plots and analysis using one-way ANOVA multiple comparisons test. Values were expressed as 
means ± SE and p values of < 0.05 were considered statistically significant, a value of **p<0.01, 
***p<0.001 and ***p<0.0001.  
 
Figure 3. Molecular model of the structural analysis of V5 and V3.  A. MyBP-C WT 3D 
structure. B. Structural comparison of WT vs V3. C. Structural comparison of WT vs V5. Both 
V5 and V3 deviated structurally and rearranged differently from the WT illustrated mainly in 
elements rearrangement at the motif region. D. Root mean square deviation (RMSD) calculation 
of the representative structures from molecular dynamics simulations illustrated that V3 
conformational deviation appeared to be flexible, while V5 showed more rigid behavior. E. 
Secondary structural change analysis of intra-molecular consequences. V3 model illustrated 
reduced β-sheets content and increased coils content compared to WT, however, V5 showed 
inverse behavior. This analysis correlated with the deviation analysis and explained the 
flexibility of V3 as there is increase of coils and for the rigidity of V5 due to the reduction of 
coils and increase of E-sheets contents. 
  
Figure 4. Expression, purification and intein cleavage of C0-C2 (MyBP-C) recombinant 
protein fragment. A. Schematic diagram showing the C0-C2 domains fragment and its 
proposed interaction with cardiac actin. B. Analysis of recombinant expression and purification 
of C0-C2 fragment protein of WT, V1, V2, V3, V4 and V5 (V3+V4) of equivalent volumes at 
12% SDS-PAGE by Coomassie staining and western blot with a polyclonal MyBP-C antibody 
(1:1000 dilution). C. MyBP-C circular dichroism (CD) spectra measurements at 25°C. All 
variants disrupted the structure of the protein fragment leading to conformations with altered 
secondary structure characteristics impacting the fragment elements; predominantly the β-sheet, 
random coil content and helical content when compared to WT. However, V5 (double mutation) 
resulted in the most altered secondary structure in comparison to WT. (WT:black, V1:red, 
V2:green, V3:blue, V4:cyan and V5:pink).  
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Figure 5. Thermal denaturation profile of MyBP-C recombinant protein fragments 
measured as normalized CD signal at 208 nm. The thermal denaturation curve of WT, V1, V2, 
V3 and V4 reveals the presence of two consecutive unfolding transitions at which the first 
thermal transition occurs in the temperature range 50°C - 65°C and the second in the temperature 
range 65°C - 90°C. while, in contrast, the melting profile of V5 indicated only the first unfolding 
transition at 50°C - 65°C, indicating that no further aggregation occurs after ~60°C for this 
fragment.  
 
Figure 6. Chemical denaturation trace of MyBP-C recombinant protein fragments. 
Changes in the weighted average emission wavelength (excitation 295 nm) of MyBP-C WT and 
the different variants were measured in solution upon titration with increasing amounts of the 
chemical denaturant guanidine hydrochloride (GuHCl). All MyBP-C fragments had displayed 
reversible transition presented by Sigmoidal two-state denaturation curves for the fraction of 
unfolding. Calculated Gibbs free energy change (ΔG) of the unfolding process illustrated 
increased stability for all variants except V5 in comparison to WT. 
 
Figure 7. Co-sedimentation binding assays of MyBP-C C0-C2 recombinant proteins and 
cardiac actin (c-actin). MyBP-C C0-C2 recombinant proteins (2 μM) were incubated with c-
actin at RT for 30 min and spun for 1 hour at 14,000 g. The amount of MyBP-C C0-C2 proteins 
in supernatant (unbound fraction) was analyzed by SDS-PAGE and quantified by Coomassie 
brilliant blue and densitometric analysis. (A) Optimization experiments using 2 μM of MyBP-C 
C0-C2 WT and 20 or 30 μM c-actin showing that saturated binding is achieved with 30 μM c-
actin. (B) Representative SDS-PAGE gel and Coomassie brilliant blue staining following MyBP-
C C0-C2 mutant protein-c-actin co-sedimentation assays showing the amounts of MyBP-C C0-
C2 mutant proteins in supernatant fractions (unbound fraction) pre (-) and post (+) co-
sedimentation with 30 μM c-actin. (C) Densitometric analysis and % normalization of the 
binding of MyBP-C C0-C2 recombinant proteins to 30 μM c-actin. Significant effects (asterisks) 
were calculated by comparison to the binding of WT MyBP-C C0-C2 using an unpaired 
Student’s t-test. n = 2 ± S.E.M., *p<0.05 and **p<0.01, (GraphPad Prism 7). 
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Tables 
 
Table 1 
Variant a 
(V) 
c-MYBPC3 c MyBP-C d ExAC allele 
frequency e 
MyBP-C Domain Years f Thickness g 
(mm) 
HCM patients 
clinical symptoms 
Classification of 
Pathogenicity h 
Reference 
V1 c.530G>A p.Arg177His 0.0009493 
C1 (Ig-like C2-type 
1) 
56 15 Chest pain 
Unlikely to be 
pathogenic 
(Jaafar, Gómez 
et al. 2016) 
V2 c.646G>A p.Ala216Thr   0.000365 
C1 (Ig-like C2-type 
1) 
34 N/R 
Sub-aortic 
occlusion 
Class 3-
Unknown 
pathogenicity 
(Rodríguez-
García, 
Monserrat et al. 
2010) 
V3 c.772G>A p.Glu258Lys   3.9E-05 
M-motif 
(phosphorylation site) 
49 15 
chest pain and 
palpitation, chest 
pain and dyspnea 
Class 5-
Certainly 
pathogenic 
(Jaafar, Gómez 
et al. 2016) 
V4 c.1321G>A p.Glu441Lys   0.000162 
C2 (Ig-like C2-type 
2) 
45 23.2 
no syncope, 
complaint about 
angina at exertion, 
but no ventricular 
tachycardia 
Class 3-
Unknown 
pathogenicity 
(Marsiglia, 
Batitucci et al. 
2010) 
V5 b 
(V3 + 
V4) 
c.772G>A  
+c.1321G>A 
p.(Glu258Lys 
+ Glu441Lys) 
- 
M motif and C2       
(Ig-like C2-type 2) 
21 22 
dyspnea, 
progressive heart 
failure with 
repeated 
hospitalizations 
then patient died at 
age 42 
Class 5-
Certainly 
pathogenic 
(Gajendrarao, 
Krishnamoorthy 
et al. 2015) 
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Table 2 
Protein α-Helix 
β-Sheet 
β-Turn Random Coil 
Antiparallel Parallel 
WT 20.7% 11.3% 13.6% 18.9% 40.2% 
V1 26.8% 21.2% 8.9% 19.1% 28.1% 
V2 26.4% 11.1% 10.6% 18.4% 36.4% 
V3 26.8% 14.4% 9.9% 18.2% 33.7% 
V4 26.0% 10.6% 10.7% 18.4% 38.5% 
V5 26.8% 21.2% 8.9% 19.1% 28.5% 
 
 
Table 3 
Protein 
m 
(kcal mol-1 M-1) 
D50% 
(M) 
ΔGDN 
(kcal mol-1) 
WT 2.07 ± 0.15 1.67 ± 0.05 3.46 ± 0.27 
V1 2.45 ± 0.19 1.66 ± 0.05 4.07 ± 0.34 
V2 2.25 ± 0.15 1.77 ± 0.03 3.98 ± 0.27 
V3 2.90 ± 0.21 1.69 ± 0.03 4.90 ± 0.37 
V4 2.83 ± 0.20 1.76 ± 0.03 4.98 ± 0.36 
V5 2.03 ± 0.16 1.56 ± 0.03 3.17 ± 0.26 
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